A Strategic Vision For 21st Century Drug Discovery By Dr Wayne Bowen, Dr Giles Sanders, Dr Andreas Werdich, Dr Brian Warrington and Dr Elizabeth Farrant Delivering genuine therapeutic innovation is more challenging and complex than ever. Despite major scientific breakthroughs and technological advances leading to a greater… Read More
Translational Chemical Biology: Gap assessment for advancing drug discovery, development and precision medicine By Dr Mukund Chorghade, Dr Michael Liebman, Dr Gerald Lushington, Dr Stephen Naylor and Dr Rathnam Chaguturu As yesterday’s lead molecule enters today’s clinical trial, the standard operating script seems to call for product developers… Read More
By Dr Paul Denny-Gouldson For many years we have used the term bioinformatics to describe, well, anything outside cheminformatics in the R&D informatics domain. It has been a ‘catch-all’ term to label informatics tools that handle biologically relevant information. But the tools and software that… Read More
I Robot. I, The Future – Robotics Within and Beyond The Lab Richard Holland The Pistoia Alliance (whose membership includes most of the world’s major pharmaceutical companies, technology vendors and publishers active in the life science R&D sector), is keenly interested in discovering the ways in which innovation… Read More
CRISPR Cas9: Transforming Gene Editing in Drug Discovery Labs By Dr John Comley It is evident from a recent market survey on gene editing in drug discovery that CRISPR/Cas9 is now recognised as the superlative method when attempting a gene knockout or when introducing defined mutations, insertions… Read More
By Dr A Roy, Prof B Patwardhan and Dr R Chaguturu Modern drug discovery approaches take too long, are too expensive, have too many clinical failures and uncertain outcomes. There are many reasons for this unsustainable business model, but primarily, the approaches are not comprehensively… Read More
With Synthetic Biology, Drug Discovery Is Going Virtual by Christopher Voigt Christopher Voigt is a professor of biological engineering at the Massachusetts Institute of Technology, where his lab focuses on synthetic biology. Two major areas of interest for him are developing a genetic programming language for cells and… Read More
Full Length Isoform Sequencing (Iso-Seq) Yields a More Comprehensive View of Gene Activity By Luke Hickey RNA-seq has revolutionised how scientists can interrogate gene expression. But after years of performing RNA-seq studies with short-read sequencers, many have realised that there is more to be discovered. Read More
By Dr James Lim and Dr Fred Aswad While the use of human cell lines has become a permanent fixture in drug discovery and development, the lingering issue has been in their inconsistent results. This article discusses current attempts to make results from… Read More
Synthetic Lethality and Anti Cancer Drug Discovery By Jonathan D Moore Classically-activated oncogene targets have been a mainstay of cancer drug discovery for the past 15 years, but the druggable targets in this category have been largely mined out. Future efforts to drug the… Read More
Drug Discovery in a Multi-Omics World By Mike Furness Collectively rare diseases affect millions of people worldwide, but the number of people with any one condition is very small. Finding a cure is difficult as the market is not large enough to justify a big investment in drug… Read More
Therapeutic Drug Repurposing, Repositioning and Rescue Part IV: Financial model and analysis By David M. Kauppi and Dr Stephen Naylor There is a growing consensus that Drug Repurposing, Repositioning and Rescue (DRPx) impacts all stakeholders involved in the therapeutic drug sector. In… Read More
New Developments in Single Cell Separation and Analysis Technologies By Dr John Comley Drug Discovery Recent advances of single cell technologies are facilitating the opportunity to discern biological insights within individual cells and providing a means to reveal previously hidden relationships between individual cells within a population. Read More
Therapeutic Drug Repurposing, Repositioning and Rescue Part III: Market exclusivity using Intellectual Property and regulatory pathways By Dr Stephen Naylor, David M. Kauppi and Judge M. Schonfeld There is a growing consensus that Drug Repurposing, Repositioning and Rescue (DRPx) can impact the prescription drug industry for all concerned… Read More
Individualised Systems Medicine: Next-Generation Precision Cancer Medicine and Drug Positioning By Tea Pemovska, Paaivi Östling, Caroline Heckman, Olli Kallioniemi and Krister Wennerberg A growing number of oncology drugs are currently clinically available and more than a thousand compounds are being developed for oncology indications. Read More
Epigenetic Targets: On the verge of becoming a major new category for successful drug research By Dr John Comley Most vendors of epigenetic modification proteins and reagents have enhanced and broadened their offerings in recent years. Of particular note is the increasing range of proteins and binding… Read More